Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lisocabtagene Maraleucel
Related studies linked through entity extraction aliases.
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Status
- RECRUITING
- Phase
- PHASE3
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
- Status
- RECRUITING
- Phase
- N/A
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
- Status
- RECRUITING
- Phase
- N/A
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
- Status
- RECRUITING
- Phase
- N/A
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Status
- RECRUITING
- Phase
- N/A
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
- Status
- RECRUITING
- Phase
- PHASE2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
- Status
- COMPLETED
- Phase
- PHASE1
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
- Status
- COMPLETED
- Phase
- PHASE2
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
- Status
- COMPLETED
- Phase
- PHASE2